Balar AV, Kamat AM, Kulkarni GS, Uchio EM, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021 May 26. pii: S1470-2045(21)00147.
PMID: 34051177